Investigating the Varied Efficacy of Ozempic and Wegovy in Weight Loss

Research explores why weight-loss drugs like Ozempic and Wegovy yield different results among users, focusing on metabolic responses.

A
Aapla Nagpur Desk
19 Nov 2026, 2:15 PM IST · 2 min read
Source: Sciencedaily
Investigating the Varied Efficacy of Ozempic and Wegovy in Weight Loss
KEY TAKEAWAYS
1

Ozempic and Wegovy can reduce body weight by an average of 15% over 68 weeks.

2

Individual responses to these medications may depend on genetics, metabolism, and lifestyle factors.

3

Understanding energy metabolism could lead to more effective, personalized weight-loss treatments.

A recent study from the University of Alberta has shed light on the inconsistent results of weight-loss medications such as Ozempic and Wegovy. While these drugs, which contain semaglutide, have been shown to produce significant weight loss in some individuals, others experience minimal or no results. The research team is investigating the body's energy-saving responses as a potential explanation for these disparities, aiming to develop more effective, tailored treatments for obesity.

Semaglutide, a GLP-1 receptor agonist, is recognized for its ability to regulate blood sugar and appetite, leading to an average weight reduction of 15% when combined with lifestyle changes over a period of 68 weeks. However, the effectiveness of these medications varies among individuals. The research team is focused on understanding the factors that contribute to these differences, including genetics, metabolism, body composition, and lifestyle choices.

One significant aspect under investigation is energy metabolism, which refers to the balance between calories consumed and calories burned. When individuals lose weight, their bodies often require less energy, sometimes entering an 'energy-saving mode' that makes further weight loss more challenging. This phenomenon, known as metabolic adaptation, can result in a plateau in weight loss efforts, complicating long-term success.

The implications of this research extend beyond individual weight loss. By identifying how semaglutide affects energy utilization and body composition, researchers hope to create more personalized approaches to obesity treatment. This could lead to better management strategies for individuals with Type 2 diabetes and obesity, ultimately improving health outcomes.

Looking ahead, the University of Alberta's research team is actively recruiting participants who are starting semaglutide treatment. Over the next six months, they will monitor changes in body weight, composition, and energy utilization. This study aims to clarify the relationship between semaglutide and energy metabolism, paving the way for more effective obesity treatments in the future.

💬What did you think of this story?What did you think?

Read Next

Ozempic and Wegovy Weight Loss Study Insights